<DOC>
	<DOCNO>NCT00802815</DOCNO>
	<brief_summary>Inclusion body myositis ( IBM ) common late onset acquire muscle disease . Patients develop progressive weakness may result need assistive device include wheelchair . IBM may due abnormal immune activation , due part overproduction tumor necrosis factor ( TNF ) -alpha . Etanercept block activity TNF-alpha , thereby blunt immune overactivation . Previous unblinded study case report suggest etanercept may improve strength slow progressive weakness IBM . We conduct double-blind , randomize , placebo-controlled study test Etanercept beneficial slow progressive weakness patient IBM .</brief_summary>
	<brief_title>Double-blind , Randomized , Placebo-controlled Trial Etanercept 12 Months Subjects With Inclusion Body Myositis</brief_title>
	<detailed_description>Travel expense cover study .</detailed_description>
	<mesh_term>Myositis</mesh_term>
	<mesh_term>Myositis , Inclusion Body</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>A clinical diagnosis definite probable IBM . Male female age 1880 . Subjects must able provide inform consent . Subjects must immunosuppressive medication 3 month agree take immunosuppressive medication study . Subjects must sulfasalazine Subjects caregiver must able administer SQ medication . Women childbearing potential ( postmenopausal surgically sterile ) must negative pregnancy test screen use adequate birth control . Absence exclusion criterion . Exposure etanercept within 3 month study entry Exposure investigational drug within 3 month study entry . Subject know hypersensitivity etanercept . Subject active medical psychiatric condition opinion principal investigator , may affect interpretation safety efficacy data otherwise contraindicate participation study . Signs , symptoms laboratory evidence severe renal , pulmonary , hepatic , neurologic , cardiac ( congestive heart failure , coronary artery ) disease , include creatinine &gt; 2.0 , LFT &gt; 2x upper limit normal hemoglobin &lt; 12.5 ( male ) &lt; 11.0 ( female ) . Subject weakness neurological neuromuscular disease , include multiple sclerosis CNS demyelinate disease . Subject sepsis active , chronic , local infection antibiotic , antiviral antifungal medication within 3 month prior first dose Etanercept . A prior history tuberculosis and/or positive PPD skin test screening ( include read borderline , reactive nondiagnostic ) prior inoculated subject . Human immunodeficiency virus infection . Subject history opportunistic infection . Subject known history antiJo1 , antiSRP antiMI2 antibody . The presence associate connective tissue disease , include systemic lupus erythematous , Sj√∂gren 's syndrome , scleroderma mixed connective tissue disease . History new diagnosis treatment invasive malignancy within 5 year enrollment , include patient history squamous cell carcinoma basal cell carcinoma . History drug alcohol abuse within 1 year prior study entry . Unwillingness practice effective contraception , except female patient postmenopausal surgically sterile . The rhythm method use sloe method contraception . Subjects receive live vaccine study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>